MetaCap

Inovio Pharmaceuticals (INO) vs Larimar Therapeutics (LRMR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Inovio Pharmaceuticals (INO) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 0.0% versus a loss of 11.8%. Over five years, LRMR leads with a -69.0% price change compared with -98.0% for INO. Inovio Pharmaceuticals is the larger company by market cap ($329.7 million vs $328.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INO0.00%LRMR-11.80%
+74%+1%-73%
Nov 21, 20251 yearNov 20, 2026
INO-98.00%LRMR-69.37%
+31%-37%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INO versus LRMR key metrics
MetricINOLRMR
Share price$1.76$3.14
Market cap$329.66M$328.55M
1-day change+2.92%-2.48%
YTD return+1.15%-17.59%
1-year return0.00%-11.80%
5-year return-97.98%-68.97%
EPS (TTM)$-0.59$-1.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$65.34K—
Revenue growth (YoY)-69.99%—
Net income (latest FY)$-84.95M$-165.67M
Operating margin-132871.32%—
Net margin-130000.00%—
52-week high$2.72$6.42
52-week low$0.56$1.92
Distance from 52-week high-35.29%-51.09%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+259.66%+352.23%
Average volume11.24M1.38M
Shares outstanding187.31M104.63M
Employees11271
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INO has outperformed LRMR by 11.8 percentage points over the past year.

About Inovio Pharmaceuticals

INO stock →

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees

About Larimar Therapeutics

LRMR stock →

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees

INO vs LRMR FAQ

Which is bigger, Inovio Pharmaceuticals or Larimar Therapeutics?

Inovio Pharmaceuticals (INO) is larger, with a market capitalization of $329.66M compared with $328.55M for Larimar Therapeutics (LRMR).

Which stock has performed better over the past year, INO or LRMR?

INO returned 0.00% over the past 12 months, compared with -11.80% for LRMR (price return, excluding dividends). Past performance does not predict future results.

Are Inovio Pharmaceuticals and Larimar Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons